173 related articles for article (PubMed ID: 31659661)
1. Medication Non-adherence in a Prospective, Multi-center Cohort Treated with Hepatitis C Direct-Acting Antivirals.
Serper M; Evon DM; Stewart PW; Lok AS; Amador J; Reeve BB; Golin CE; Fried MW; Reddy KR; Sterling RK; Sarkar S; Di Bisceglie AM; Lim JK; Nelson DR; Reau N
J Gen Intern Med; 2020 Apr; 35(4):1011-1020. PubMed ID: 31659661
[TBL] [Abstract][Full Text] [Related]
2. Understanding real-world adherence in the directly acting antiviral era: A prospective evaluation of adherence among people with a history of drug use at a community-based program in Toronto, Canada.
Mason K; Dodd Z; Guyton M; Tookey P; Lettner B; Matelski J; Sockalingam S; Altenberg J; Powis J
Int J Drug Policy; 2017 Sep; 47():202-208. PubMed ID: 28619394
[TBL] [Abstract][Full Text] [Related]
3. Virological and Clinical Outcome of DAA Containing Regimens in a Cohort of Patients in Calabria Region (Southern Italy).
Scaglione V; Mazzitelli M; Costa C; Pisani V; Greco G; Serapide F; Lionello R; La Gamba V; Marascio N; Trecarichi EM; Torti C
Medicina (Kaunas); 2020 Feb; 56(3):. PubMed ID: 32121135
[No Abstract] [Full Text] [Related]
4. Excess Weight Gain After Cure of Hepatitis C Infection with Direct-Acting Antivirals.
Do A; Esserman DA; Krishnan S; Lim JK; Taddei TH; Hauser RG; Tate JP; Re VL; Justice AC
J Gen Intern Med; 2020 Jul; 35(7):2025-2034. PubMed ID: 32342483
[TBL] [Abstract][Full Text] [Related]
5. Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy.
Macías J; Morano LE; Téllez F; Granados R; Rivero-Juárez A; Palacios R; Ríos M; Merino D; Pérez-Pérez M; Collado A; Figueruela B; Morano A; Freyre-Carrillo C; Martín JM; Rivero A; García F; Pineda JA;
J Hepatol; 2019 Jul; 71(1):45-51. PubMed ID: 30853642
[TBL] [Abstract][Full Text] [Related]
6. HCV eradication in veterans with underlying mental health disorders and substance use.
Ifeachor AP; Houck KK; Schulte S; Ansara E; Johnson AJ; Carr TA; Liangpunsakul S
J Am Pharm Assoc (2003); 2020; 60(6):1037-1043.e3. PubMed ID: 32948462
[TBL] [Abstract][Full Text] [Related]
7. Direct patient-physician communication via a hepatitis C hotline facilitates treatment initiation in patients with poor adherence.
Steininger L; Chromy D; Bauer D; Simbrunner B; Binter T; Schwabl P; Schmidbauer C; Trauner M; Gschwantler M; Mandorfer M; Reiberger T
Wien Klin Wochenschr; 2021 May; 133(9-10):452-460. PubMed ID: 33351152
[TBL] [Abstract][Full Text] [Related]
8. Sustained Virologic Response of Patients Hospitalized Compared With Those Not Hospitalized During Treatment for Hepatitis C Virus With Direct-Acting Antivirals.
Gentene AJ; Bell AM; Pence A; Thomas K; Jakubecz C; Stacy E; Woolf B; Guido MR; Mueller EW; Sherman KE
Ann Pharmacother; 2021 May; 55(5):565-574. PubMed ID: 33016095
[TBL] [Abstract][Full Text] [Related]
9. Management of drug interactions with direct-acting antivirals in Dutch HIV/hepatitis C virus-coinfected patients: adequate but not perfect.
Smolders EJ; Smit C; de Kanter C; Dofferhoff A; Arends JE; Brinkman K; Rijnders B; van der Valk M; Reiss P; Burger DM;
HIV Med; 2018 Mar; 19(3):216-226. PubMed ID: 29194939
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis C virus direct-acting antiviral nonadherence: Relationship to sustained virologic response and identification of at-risk patients.
Slevin AR; Hart MJ; Van Horn C; Rahman S; Samji NS; Szabo A; Rein L; Werner S; Saeian K
J Am Pharm Assoc (2003); 2019; 59(1):51-56. PubMed ID: 30545782
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C Virus Direct-Acting Antiviral Treatment Adherence Patterns and Sustained Viral Response Among People Who Inject Drugs Treated in Opioid Agonist Therapy Programs.
Heo M; Pericot-Valverde I; Rennert L; Akiyama MJ; Norton BL; Gormley M; Agyemang L; Arnsten JH; Litwin AH
Clin Infect Dis; 2021 Dec; 73(11):2093-2100. PubMed ID: 33876230
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of direct-acting antiviral therapy for hepatitis C in difficult-to-treat patients in a safety-net health system: a retrospective cohort study.
Yek C; de la Flor C; Marshall J; Zoellner C; Thompson G; Quirk L; Mayorga C; Turner BJ; Singal AG; Jain MK
BMC Med; 2017 Nov; 15(1):204. PubMed ID: 29151365
[TBL] [Abstract][Full Text] [Related]
13. Direct acting antiviral treatment of chronic hepatitis C in Denmark: factors associated with and barriers to treatment initiation.
Sølund C; Hallager S; Pedersen MS; Fahnøe U; Ernst A; Krarup HB; Røge BT; Christensen PB; Laursen AL; Gerstoft J; Bélard E; Madsen LG; Schønning K; Pedersen AG; Bukh J; Weis N;
Scand J Gastroenterol; 2018; 53(7):849-856. PubMed ID: 29720023
[TBL] [Abstract][Full Text] [Related]
14. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
Prenner SB; VanWagner LB; Flamm SL; Salem R; Lewandowski RJ; Kulik L
J Hepatol; 2017 Jun; 66(6):1173-1181. PubMed ID: 28161470
[TBL] [Abstract][Full Text] [Related]
15. Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study.
Colussi G; Donnini D; Brizzi RF; Maier S; Valenti L; Catena C; Cavarape A; Sechi LA; Soardo G
World J Gastroenterol; 2019 Oct; 25(40):6094-6106. PubMed ID: 31686765
[TBL] [Abstract][Full Text] [Related]
16. Identifying Barriers to the Treatment of Chronic Hepatitis C Infection.
Al-Khazraji A; Patel I; Saleh M; Ashraf A; Lieber J; Malik R
Dig Dis; 2020; 38(1):46-52. PubMed ID: 31422405
[TBL] [Abstract][Full Text] [Related]
17. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
Cabibbo G; Celsa C; Calvaruso V; Petta S; Cacciola I; Cannavò MR; Madonia S; Rossi M; Magro B; Rini F; Distefano M; Larocca L; Prestileo T; Malizia G; Bertino G; Benanti F; Licata A; Scalisi I; Mazzola G; Di Rosolini MA; Alaimo G; Averna A; Cartabellotta F; Alessi N; Guastella S; Russello M; Scifo G; Squadrito G; Raimondo G; Trevisani F; Craxì A; Di Marco V; Cammà C;
J Hepatol; 2019 Aug; 71(2):265-273. PubMed ID: 30959157
[TBL] [Abstract][Full Text] [Related]
18. Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting.
Read P; Lothian R; Chronister K; Gilliver R; Kearley J; Dore GJ; van Beek I
Int J Drug Policy; 2017 Sep; 47():209-215. PubMed ID: 28587943
[TBL] [Abstract][Full Text] [Related]
19. High rate of sustained virological response with direct-acting antivirals in haemophiliacs with HCV infection: A multicenter study.
Mancuso ME; Linari S; Santagostino E; Bartolozzi D; D'Ambrosio R; Borghi M; Lampertico P; Peyvandi F; Castaman G; Aghemo A
Liver Int; 2020 May; 40(5):1062-1068. PubMed ID: 31876354
[TBL] [Abstract][Full Text] [Related]
20. Health Insurance and Initiation of Direct-Acting Antivirals for Hepatitis C in US Women With Human Immunodeficiency Virus.
Edmonds A; Haley DF; Edwards JK; Ramirez C; French AL; Tien PC; Plankey M; Sharma A; Augenbraun M; Seaberg EC; Workowski K; Alcaide ML; Albrecht S; Adimora AA
Clin Infect Dis; 2023 Jul; 77(2):258-264. PubMed ID: 37021689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]